The Potential Revolution of Cancer Treatment with CRISPR Technology
Dimitrios Stefanoudakis(APLA Health), Alexandra Drakaki(Columbia University Irving Medical Center), Claire Drolen(University of California, Los Angeles), Gavin Hui(University of California, Los Angeles), Yuliya Zektser(University of California, Los Angeles), Nikhita Kathuria‐Prakash(University of California, Los Angeles), Lidia López(University of California, Los Angeles), Yeganeh A. Tabatabaei(University of California, Los Angeles), Alexander W. Sun(Columbia University), Shiliang Zhang(University of California, Los Angeles), Camille Ashbaugh(University of California, Los Angeles), Allan J. Pantuck(University of California System), Melissa L. Abel(National Institutes of Health)
Cited by 63
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78